Novo Nordisk, the maker of weight loss drug Wegovy, will lay off about 9,000 people as it grapples with rising competition in ...

The pharmaceutical giant is slashing 11% of its workforce as it continues to lose market share. Novo Nordisk, the Danish ...

The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative ...

Novo Nordisk A/S (NYSE:NVO) on Sunday presented data from the STEER real-world study of evidence gathered from actual patient ...

A class-action lawsuit accuses CVS Caremark of denying medically necessary treatments by stopping coverage of Zepbound, Eli ...

Eli Lilly dominates obesity and diabetes treatments with soaring tirzepatide sales and promising oral drug data. Find out why ...

Novo Nordisk (NVO) stock in focus as its obesity drug Wegovy outperforms Eli Lilly's (LLY) rival Zepbound in reducing serious ...

The restructuring, which would eliminate 11% of the company's workforce, aimed to reduce organizational complexity and speed ...

Novo Nordisk will cut 9,000 jobs in a global restructuring, targeting annual savings of $1.26 billion, as it faces ...

The study used evidence gathered from patient experiences rather than a controlled trial, Novo said.

Novo Nordisk, the maker of blockbuster weight-loss drug Wegovy, said on Wednesday it will cut 11.5% of its workforce in an ...

While a recent head-to-head trial of the obesity med heavyweights Wegovy and Zepbound favored the latter drug from Eli Lilly on weight loss, Novo Nordisk has now countered that result with ...